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Type 2 diabetes is a major cause of cardiovascular disease. We have determined whether the metabolic and cardiovascular changes
induced by a diet high in fructose in young adult male Wistar rats could be prevented or reversed by chronic intervention with
natural antioxidants. We administered a regenerative antioxidant protocol using two natural compounds: α-lipoic acid together
with vitamin E (α-tocopherol alone or a tocotrienol-rich fraction), given as either a prevention or reversal protocol in the food.
These rats developed glucose intolerance, hypertension, and increased collagen deposition in the heart together with an increased
ventricular stiffness. Treatment with a fixed combination of vitamin E (either α-tocopherol or tocotrienol-rich fraction, 0.84 g/kg
food) and α-lipoic acid (1.6 g/kg food) normalized glucose tolerance, blood pressure, cardiac collagen deposition, and ventricular
stiffness in both prevention and reversal protocols in these fructose-fed rats. These results suggest that adequate antioxidant therapy
can both prevent and reverse the metabolic and cardiovascular damage in type 2 diabetes.
1. Introduction
The epidemic of type 2 diabetes now affects approximately
150 million people worldwide, with a projected incidence of
300 million by the year 2025 [1, 2]. This epidemic has been
attributed to high fat/high sugar intakes in modern diets,
correlating with the increased use of fructose as a sweetener
[1]. Dietary fructose undergoes rapid metabolism by the
liver, causing changes in carbohydrate and lipid metabolism
and hepatic inflammation leading to the development of
hyperglycemia, insulin resistance, hyperinsulinemia, and
hypertriglyceridemia as major risk factors for diabetic com-
plications [2–4]. Rats fed a high fructose diet mimic the
progression of type 2 diabetes seen in humans including
glucose intolerance, increased oxidative stress, hypertension,
and reduced myocardial and vascular compliance [5–9].
Fructose feeding initiates an increased mitochondrial for-
mation of reactive oxygen species and, as a consequence,
oxidative stress [10], producing hypertension and decreased
myocardial compliance, as evidenced by improvements in
symptoms following antioxidant therapy [11–13].
Naturally occurring antioxidants include vitamin E, a
family of naturally occurring tocopherols and tocotrienols
[14]. While many studies suggest that antioxidant com-
pounds such as vitamin E decrease the risk of cardiovascular
disease, there has been conflicting evidence of its efficacy
when administered alone, along with probable toxicity from
high levels of supplementation [14, 15]. The water and lipid-
soluble antioxidant, α-lipoic acid, decreased reactive oxygen
species both at the cell surface and in the mitochondria,
increasing uptake of glucose through increasing insulin
sensitivity at key muscular sites as well as recycling vitamin E
[16, 17]. Treatment with α-lipoic acid improved endothelial
dysfunction, reduced oxidative stress, improved plasma
lipid profiles, and improved insulin sensitivity in high fat-
fed Goto-Kakizaki diabetic rats [18]. The combination of
vitamin E and α-lipoic acid as a regenerative antioxidant
protocol improved cardiac performance in aged rats [19].
This study has determined whether treatment with a
regenerative antioxidant protocol of vitamin E (either α-
tocopherol or a tocotrienol-rich fraction) together with α-
lipoic acid can prevent or reverse the cardiovascular and
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metabolic changes observed with chronic fructose feeding in
rats.
2. Materials and Methods
2.1. Rats. Male Wistar rats (8–10 weeks old weighing
349 ± 8 g; n = 60) were obtained from The University of
Queensland Biological Resources. The animals were housed
in separate cages at the Animal House Facility of the School
of Biomedical Sciences, The University of Queensland. Rats
were given ad libitum access to specific food diets and
water and were housed in a 12-hour light/dark environment.
All experimental protocols were approved by the Animal
Experimentation Ethics Committee of The University of
Queensland following the guidelines of the National Health
and Medical Research Council of Australia.
2.2. Experimental Groups. Rats were fed a diet consisting
of fructose (610 g), skim milk powder (200 g), wheat bran
(96 g), peanut oil (50 g), Hubbell, Mendel, and Wakeman
salt mixture (35 g), and L-methionine (7 g) per kilogram of
food [2, 3, 6]. For the control group, fructose was substituted
with corn starch (610 g) [2, 3, 6]. Rats were divided into 6
experimental groups. These groups were (i) corn starch (CS)
(n = 10), (ii) fructose (F) (n = 10), (iii) fructose + α-lipoic
acid/α-tocopherol prevention (FTPP) (n = 10), (iv) fruc-
tose + α-lipoic acid/α-tocopherol reversal (FTPR) (n = 10),
(v) fructose + α-lipoic acid/tocotrienol prevention (FTTP)
(n = 10), and (vi) fructose + α-lipoic acid/tocotrienol
reversal (FTTR) (n = 10). Diets were administered to the
rats for 16 weeks to allow both induction of significant
metabolic and cardiovascular changes as characterized in our
previous study [6] and possible reversal of these diet-induced
changes for the final 8 weeks of the protocol [2, 3]. The
prevention protocols received α-lipoic acid with either α-
tocopherol (group (iii)) or tocotrienol-rich fraction (group
(v)) for the full 16 weeks of the diet; the reversal protocols
(groups (iv) and (vi)) received these supplements for 8 weeks
starting after 8 weeks of the fructose diet. Supplemented
diets contained α-lipoic acid (1.6 g/kg food) and either
α-tocopherol (0.84 g/kg food) or tocotrienol-rich fraction
(1.56 g/kg food contributing 0.84 g/kg food of a mixture of
α-tocopherol and tocotrienols).
2.3. Assessment of Physiological Parameters. Body weight and
food and water intakes were measured daily. Systolic blood
pressure was measured after 0, 4, 8, 12, and 16 weeks
under light sedation with i.p. injection of Zoletil (tiletamine
15mg/kg, zolazepam 15mg/kg), using an MLT1010 Piezo-
Electric Pulse Transducer (ADInstruments) and inflatable
tail-cuff connected to an MLT844 Physiological Pressure
Transducer (ADInstruments) and PowerLab data acquisition
unit (ADInstruments, Sydney, Australia). Rats were killed
with an intraperitoneal (i.p.) injection of pentobarbitone
sodium (100mg/kg). Blood was taken from the abdominal
aorta and centrifuged; the plasma was collected and frozen.
Plasma malondialdehyde concentrations were determined by
HPLC [20].
2.4. Oral Glucose Tolerance Test. Testing was performed
after 0, 4, 8, 12, and 16 weeks of diet. After 12 hours
of fasting, blood glucose concentrations were measured in
blood samples taken from the tail vein. Subsequently, each
rat was treated with glucose (2 g/kg) via oral gavage. Tail
vein blood samples were taken every 30 minutes up to 120
minutes following glucose administration. The blood glucose
concentrations were analyzed with a Medisense Precision
Q.I.D glucose meter (Abbott Laboratories, Bedford, USA).
2.5. Isolated Heart Preparation. The left ventricular function
of the rats in all treatment groups was assessed using the Lan-
gendorff heart preparation. Terminal anesthesia was induced
via i.p. injection of pentobarbitone sodium (100mg/kg).
Once anesthesia was achieved, heparin (1000 IU) was
injected into the right femoral vein. After removal of the
heart, isovolumetric ventricular function was measured by
inserting a latex balloon catheter into the left ventricle
connected to a Capto SP844 MLT844 physiological pressure
transducer and Chart software on a Maclab system. All left
ventricular end-diastolic pressure values were measured by
pacing the heart at 250 beats per minute using an electrical
stimulator. End-diastolic pressures were obtained starting
from 0mmHg up to 30mmHg. The right and left ventricles
were separated and weighed. Diastolic stiffness constant (κ,
dimensionless) was calculated as in previous studies [21, 22].
The liver, kidneys, and spleen were removed and blotted dry
for weighing. Organ weights were normalized relative to the
tibial length (mg/mm).
2.6. Confocal Microscopy. Collagen distribution was mea-
sured in the left ventricle following staining with picrosirius
red and analyzed by laser confocal microscopy. Tissues were
initially fixed for 3 days in Telly’s fixative (100mL of 70%
ethanol, 5mL of glacial acetic acid, and 10mL of 40%
formaldehyde) and transferred into modified Bouin’s fluid
(85mL of saturated picric acid, 5mL of glacial acetic acid,
and 10mL of 40% formaldehyde) for 2 days. The samples
were then dehydrated and embedded in paraffin wax. Thick
sections (15 μm) were cut and stained and image analysis
under the confocal laser scanning microscope was performed
as previously described [20, 22].
2.7. Statistical Analysis. All data sets were represented as
mean ± standard error of mean (SEM). Comparisons of
findings between groups were made via statistical analysis of
data sets using either an unpaired t-test or one-way/two-way
analysis of variance (ANOVA) with Bonferroni’s multiple-
comparison test. A P value of < .05 was considered as
statistically significant.
2.8. Drugs. α-Lipoic acid and α-tocopheryl acid succinate
were obtained from Associate Professor Jeff Coombes at
the School of Human Movement Studies, The University of
Queensland. The tocotrienol-rich fraction (Gold Tri.E 70—
liquid) was provided by Golden Hope Bioganic, Selangor,
Malaysia, part of the Sime Darby group. The product
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Table 1: Physiological parameters of rats fed with corn starch, fructose, and fructose either with α-tocopherol and α-lipoic acid as prevention
(FTPP) or reversal (FTPR) protocols or with tocotrienol-rich fraction and α-lipoic acid either as prevention (FTTP) or reversal (FTTR)
protocols. aValues for rats fed the fructose diet for 8 weeks were taken from [6]. Values are mean ± SEM; number of experiments in
parentheses. LV: left ventricle; RV: right ventricle; ∗P < .05 versus corn starch-fed rats; #P < .05 versus fructose-fed rats.
Parameter
Corn starch
(16 weeks)
Fructose
(8 weeks)a
Fructose
(16 weeks)
FTPP
(16 weeks)
FTPR
(16 weeks)
FTTP
(16 weeks)
FTTR
(16 weeks)
Body weight at 0 weeks (g)
339 ± 8
(n = 10)
351 ± 10
(n = 10)
349 ± 5
(n = 10)
347 ± 10
(n = 10)
334 ± 5
(n = 10)
356 ± 5
(n = 10)
352 ± 6
(n = 10)
Body weight at 16 weeks (g)
533 ± 14
(n = 10)
459 ± 13
(n = 9)
521 ± 8
(n = 10)
502 ± 12
(n = 10)
510 ± 9
(n = 10)
493 ± 12
(n = 10)
502 ± 8
(n = 9)
Fasting plasma glucose
concentrations (mmol/L)
2.8 ± 0.2
(n = 6)
6.1 ± 0.1∗
(n = 6)
5.9 ± 0.2∗
(n = 6)
4.8 ± 0.2#
(n = 6)
4.7 ± 0.1#
(n = 6)
4.1 ± 0.3#
(n = 6)
4.3 ± 0.4#
(n = 6)
Plasma glucose concentration
(mmol/L) (after 120-minute
glucose loading)
5.9 ± 0.1
(n = 6)
8.0 ± 0.2∗
(n = 8)
9.1 ± 0.2∗
(n = 6)
6.4 ± 0.5#
(n = 6)
5.3 ± 0.1#
(n = 6)
5.0 ± 0.2#
(n = 6)
4.8 ± 0.7#
(n = 6)
LV—interstitial collagen
(% of total area)
4.6 ± 0.7
(n = 3)
N/A
18.7 ± 2.7∗
(n = 3)
12.6 ± 1.8#
(n = 3)
13.7 ± 2.3#
(n = 3)
10.8 ± 2.9#
(n = 3)
11.2 ± 1.5#
(n = 3)
Diastolic stiffness constant (κ)
20.5 ± 0.4
(n = 6)
23.9 ± 1.4∗
(n = 6)
25.8 ± 1.1∗
(n = 6)
21.1 ± 0.6#
(n = 6)
21.9 ± 0.5#
(n = 6)
17.7 ± 1.2#
(n = 6)
19.8 ± 2.0#
(n = 6)
LV + septum (mg/g body wt)
1.7 ± 0.09
(n = 6)
2.10 ± 0.07∗
(n = 8)
2.05 ± 0.1∗
(n = 6)
1.8 ± 0.05#
(n = 6)
2.1 ± 0.2∗
(n = 6)
1.9 ± 0.1#
(n = 6)
2.0 ± 0.1∗
(n = 6)
RV (mg/g body wt)
0.53 ± 0.03
(n = 6)
0.55 ± 0.03∗
(n = 11)
0.47 ± 0.02
(n = 6)
0.47 ± 0.02
(n = 6)
0.50 ± 0.05
(n = 6)
0.4 ± 0.1
(n = 6)
0.4 ± 0.1
(n = 6)
Liver (mg/g body wt)
26.7 ± 0.6
(n = 6)
36.7 ± 1.5∗
(n = 8)
39.6 ± 3.6∗
(n = 6)
29.4 ± 1.5#
(n = 6)
31.6 ± 0.8#
(n = 6)
33.3 ± 2.5∗
(n = 6)
35.2 ± 1.4∗
(n = 6)
Spleen (mg/g body wt)
2.0 ± 0.1
(n = 6)
2.1 ± 0.1
(n = 9)
2.4 ± 0.2
(n = 6)
2.0 ± 0.2
(n = 6)
2.2 ± 0.1
(n = 6)
1.9 ± 0.1
(n = 6)
2.0 ± 0.2
(n = 6)
Kidneys (mg/g body wt)
5.15 ± 0.1
(n = 6)
7.31 ± 0.2∗
(n = 8)
6.30 ± 0.4∗
(n = 6)
6.0 ± 0.2∗
(n = 6)
6.0 ± 0.3∗
(n = 6)
7.0 ± 0.3∗
(n = 6)
6.3 ± 0.2∗
(n = 6)
Plasma malondialdehyde
concentration (μmol/L)
26.9 ± 0.7
(n = 6)
42.8 ± 1.9∗
(n = 3)
33.9 ± 1.0∗
(n = 6)
27.9 ± 2.0#
(n = 6)
27.6 ± 1.6#
(n = 6)
26.4 ± 1.5#
(n = 6)
26.8 ± 2.3#
(n = 6)
contained α-tocotrienol (31.9%), β-tocotrienol (2.1%), γ-
tocotrienol (24.8%), and δ-tocotrienol (18.3%) together
with α-tocopherol (22.9%).
3. Results
3.1. Physiological and Metabolic Changes. Body weight did
not vary among fructose-fed male Wistar rats at the end
of the 16-week study protocol although chronic fructose
feeding increased left ventricular, liver, and kidney wet
weights (Table 1). Addition of the antioxidant treatments
to the fructose diet for 16 weeks prevented the increase in
left ventricular (LV) and septum weight in comparison to
age-matched fructose-fed rats. Addition of the antioxidant
treatments to corn starch-fed rats for 8 or 16 weeks did not
alter any measured parameter (data not shown).
There was an approximate doubling in fasting plasma
glucose concentration for the 16-week fructose-fed group in
comparison to age-matched controls. After 8 or 16 weeks
of the fructose-containing diet, the plasma glucose concen-
trations measured 120 minutes after oral glucose loading
were increased compared to the control group (Figure 1;
Table 1). In contrast, the prevention group had plasma
glucose concentrations similar to control rats throughout
the oral glucose tolerance testing after 8 or 16 weeks
of the dietary intervention. The reversal group showed
an increased plasma glucose concentration 120 minutes
after glucose administration at week 8 (before antioxidant
treatment had begun) but normalization of the correspond-
ing blood glucose concentrations after 8-week antioxidant
treatment at 16 weeks (Figure 1).
3.2. Cardiovascular and Oxidant Changes. Systolic blood
pressure increased in rats with the fructose diet; treatment
with antioxidants from the start of the diet prevented this
increase (Figure 2). A reversal protocol with the antioxidant
treatment starting at week 8 produced a normalization of
systolic blood pressure within 4 weeks that was maintained
until the end of the study protocol (Figure 2).
Fructose feeding increased interstitial collagen deposition
in the left ventricle (Table 1). Both prevention and reversal
protocols of antioxidant treatment attenuated interstitial col-
lagen deposition (Table 1; Figure 3). Passive diastolic stiffness
was increased in the fructose-fed group after 8 and 16 weeks
in comparison to age-matched controls (Table 1). Antiox-
idant treatment as a prevention protocol prevented this
increase in diastolic stiffness; further, rats treated as a reversal
protocol showed decreased diastolic stiffness compared to
fructose-fed rats at 16 weeks that was not different from
control rats or rats on the prevention protocol (Table 1).
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Figure 1: (a): Plasma glucose concentrations following oral gavage
of glucose (2 g/kg) recorded after 16 weeks for rats fed with corn
starch ( ), fructose (), or fructose with α-tocopherol and α-
lipoic acid as either prevention (FTPP) ( ) or reversal (FTPR) ()
protocols. ∗P < .05 versus corn starch-fed rats. (b) Plasma glucose
concentrations following oral gavage of glucose (2 g/kg) recorded
after 16 weeks for rats fed with corn starch ( ), fructose (), or
fructose with tocotrienol-rich fraction and α-lipoic acid as either
prevention (FTTP) () or reversal (FTTR) () protocols. ∗P < .05
versus corn starch-fed rats; #P < .05 versus fructose-fed rats.
Plasma malondialdehyde concentrations were increased
in fructose-fed rats. Rats treated with vitamin E and α-
lipoic acid, either as prevention or reversal protocols, showed
plasma malondialdehyde concentrations that did not differ
from control rats (Table 1).
4. Discussion
4.1. Diabetes. Administration of a fructose-rich diet (60%)
induces type 2 diabetic complications such as hyperglycemia
and hypertension and changes in the structure of target
organs such as the heart with moderate cardiac dysfunc-
tion [5, 6, 8, 9, 13]. The cardiovascular changes include
left ventricular hypertrophy and excess collagen deposition
within the interstitium of the heart leading to decreased
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Figure 2: (a): Tail-cuff measurement of systolic blood pressure
recorded at 0, 8, and 16 weeks for rats fed with corn starch ( ),
fructose (), or fructose with α-tocopherol and α-lipoic acid as
either prevention (FTPP) ( ) or reversal (FTPR) () protocols.
∗P < .05 versus corn starch-fed rats. (b) Tail-cuff measurement of
systolic blood pressure recorded at 0, 8, and 16 weeks for rats fed
with corn starch ( ), fructose (), or fructose with tocotrienol-
rich fraction and α-lipoic acid as either prevention (FTTP) () or
reversal (FTTR) () protocols. ∗P < .05 versus corn starch-fed rats;
#P < .05 versus fructose-fed rats.
myocardial function [6, 23]. Many of the complications of
chronic fructose intake are due to its rapid metabolism by the
liver, causing changes in carbohydrate and lipid metabolism
[4, 24]. These chronic changes lead to the development
of decreased glucose tolerance, insulin resistance, hyper-
insulinemia, and hypertriglyceridemia, major determinants
in the formation of type 2 diabetic complications [3, 23,
25]. Hyperglycemia initiates an increase in mitochondrial
formation of reactive oxygen species and, as a consequence,
oxidative stress [10]. This process has been linked to a
downregulation of insulin cell signaling, resulting in insulin
resistance [26, 27]. Activation of increased reactive oxygen
species production and subsequent oxidative stress therefore
plays an integral role in the development and progression of
diabetes. Previous studies with antioxidant therapy such as
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Figure 3: Representative pictures of left ventricular interstitial collagen deposition in rats fed for 16 weeks with corn starch (a), fructose (b),
fructose with α-tocopherol and α-lipoic acid as either prevention (FTPP) (c) or reversal (FTPR) (d) protocols, or fructose with tocotrienol-
rich fraction and α-lipoic acid as either prevention (FTTP) (e) or reversal (FTTR) (f) protocols.
L-arginine, N-acetylcysteine, and Avemar have demonstrated
improvement in rat models of type 2 diabetes [8, 28, 29].
Many studies have shown that other natural products may
also prevent some of the metabolic changes in diabetes [30–
36]. Our study has extended these results by showing that the
regenerative antioxidant protocol of the naturally occurring
compounds, α-lipoic acid and vitamin E, prevented or
reversed the diet-induced diabetic complications.
4.2. Antioxidants. α-Lipoic acid is soluble in both lipid and
aqueous cellular phases [16]. Therefore, in lipid phases, α-
lipoic acid is effective at reducing reactive oxygen species
and lipid peroxides in cellular membranes. Furthermore, α-
lipoic acid has increased access to the cytosol of cells since
it is water-soluble and effectively scavenges reactive oxygen
species at their mitochondrial source [17]. α-Lipoic acid is
reduced in vivo to dihydrolipoic acid, which is biologically
active with its regenerative actions on vitamin E [17]. In
humans, α-lipoic acid is synthesized in the liver, where it acts
as a cofactor for pyruvate dehydrogenase and α-ketoglutarate
dehydrogenase. These two enzymes, in particular pyruvate
dehydrogenase, are found in the mitochondria where they
catalyze the oxidative decarboxylation of pyruvate to acetyl-
coA necessary in oxidative glucose metabolism [33]. Hence,
α-lipoic acid has been implicated as a crucial component
in the conversion of plasma glucose to energy in mito-
chondria [16, 37]. In experimental animals, α-lipoic acid
provided protection against oxidative stress damage to the
insulin-secreting β-cells of the pancreas, increased glucose
metabolism and insulin sensitivity at key muscular sites,
and decreased oxidative AGEs and systolic blood pressure
[23, 38].
Vitamin E inhibits the progression of lipid peroxidation
via neutralizing reactive oxygen species at the cellular
membrane, thus maintaining the functional and structural
integrity of organs such as the cardiovascular system [16,
37]. Following the neutralization of reactive oxygen species,
vitamin E is converted to a radical, which no longer
possesses any antioxidant properties. In the presence of
dihydrolipoic acid, this radical can be converted back to
vitamin E, allowing for vitamin E to be distributed through
both dietary and regenerative means. Thus, the regenerative
process on dietary vitamin E provides a continuous cycle
of protection to the cellular structures of key organ sites
[19, 38]. In this study, we used two derivatives from the
vitamin E family, α-tocopherol and a tocotrienol-rich mix-
ture of isomers together with α-tocopherol, showing similar
responses.
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4.3. Myocardial Remodeling. Many of the cardiac changes
that occur in type 2 diabetes arise from diabetic cardiomy-
opathy, defined as systolic dysfunction and abnormalities
in left ventricular relaxation, usually seen as the first stage
of disease progression [39]. In the current study, the
isolated Langendorff heart preparation showed an increase
in diastolic stiffness, suggesting diastolic dysfunction and
a stiffer left ventricle with chronic fructose feeding. These
changes could be due to the increased interstitial collagen
deposition induced by the hyperglycemic state. This has
been previously reported in diabetic rats, where excess
collagen deposition was observed in the perivascular and
interstitial areas of the myocardium [6, 29]. Increases in
collagen deposition are linked to the excess production of
advanced glycation end-products (AGEs), as products of
nonenzymatic glycosylation in hyperglycemic states [10].
This results in excess collagen cross-linking and depo-
sition, contributing to the increased myocardial stiffness
and decreased cardiac function. Cardiovascular remodeling
occurs in both type 1 (streptozotocin-diabetic rat) and
type 2 (OLETF and high fructose) diabetic models [6, 21,
40].
4.4. Hypertension. Increases in systolic blood pressure have
been demonstrated in both animal and human studies
following the induction of type 2 diabetes [25, 41]. Many
diets of Western society are dense in carbohydrates, in
particular the monosaccharide fructose [1, 42]. Therefore,
using fructose as a diet for rodents has allowed greater
understanding of the proposed mechanisms of cardiovas-
cular dysfunction associated with type II diabetes. Fruc-
tose feeding increased plasma glucose concentrations and
induced glucose intolerance in this study, which is consistent
with other studies [6, 29, 31, 34]. Fructose feeding leads to
altered glucose metabolism, which results in the shunting
of glucose through the polyol pathway, producing increased
amounts of fructose and excess aldehyde intermediates
such as glyceraldehydes [5]. Excess plasma aldehydes play
an essential role in increasing blood pressure by binding
sulfhydryl groups of membrane proteins causing increased
peripheral vascular resistance [43]. In type 2 diabetes, there
is a reduction in the plasma concentrations of glutathione,
a reservoir for the aldehyde-binding compound cysteine
[44]. Cysteine reacts with aldehydes, breaking down the
compound to structures that are easily excreted in the bile
and urine [45]. The ability of α-lipoic acid and vitamin E
to regenerate glutathione allows plasma concentrations to be
replenished [16, 17]. α-Lipoic acid and vitamin E also reduce
the production of excess aldehydes via increasing insulin sen-
sitivity and reducing blood glucose and further by preventing
the process of lipid peroxidation, thereby reducing blood
pressure [46, 47]. Further, increased reactive free radicals due
to fructose feeding may also induce an increase in blood
pressure [48, 49]. Studies in humans and animal models
suggest a modest reduction in increased blood pressure with
dietary antioxidants [48–50] with comparable responses to
synthetic antihypertensive compounds such as captopril and
metoprolol [51, 52].
In summary, this study indicates that dietary supple-
ments using a regenerative antioxidant protocol such as
α-lipoic acid and vitamin E can prevent and reverse the
metabolic and cardiovascular changes in diet-induced type
2 diabetes.
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